4//SEC Filing
Clarke Anthony 4
Accession 0001209191-17-047582
CIK 0000949858other
Filed
Aug 2, 8:00 PM ET
Accepted
Aug 3, 8:46 PM ET
Size
9.1 KB
Accession
0001209191-17-047582
Insider Transaction Report
Form 4
Clarke Anthony
DirectorPresident & CSO
Transactions
- Award
Common Stock
2017-08-01+6,364,335→ 6,364,335 total(indirect: By Son) - Award
Common Stock
2017-08-01+4,242,890→ 4,242,890 total(indirect: By Spouse) - Award
Common Stock
2017-08-01+6,364,335→ 6,364,335 total
Footnotes (2)
- [F1]Received in exchange for 1,500 common shares of Achieve Life Science, Inc. ("Achieve") pursuant to the merger between OncoGenex Pharmaceuticals, Inc. ("OncoGenex") and Achieve (the "Merger"). On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect an 11-for-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split").
- [F2]Received in exchange for 1,000 common shares of Achieve pursuant to the Merger between OncoGenex and Achieve. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split.
Documents
Issuer
ACHIEVE LIFE SCIENCES, INC.
CIK 0000949858
Entity typeother
Related Parties
1- filerCIK 0001713368
Filing Metadata
- Form type
- 4
- Filed
- Aug 2, 8:00 PM ET
- Accepted
- Aug 3, 8:46 PM ET
- Size
- 9.1 KB